Low dose typical antipsychotics - A brief evaluation

Psychiatric Bulletin

Volumn 24, Issue 12, 2000, Pages 465-468

  Taylor, D ^a  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; PIMOZIDE; PROLACTIN; SERTINDOLE; THIORIDAZINE;

AKATHISIA; AKINESIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INFORMATION; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; PARKINSONISM; REVIEW; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

EID: 0034529276     PISSN: 09556036     EISSN: None     Source Type: Journal    
DOI: 10.1192/pb.24.12.465     Document Type: Review

References (40)

1. Comparative trial of low dose haloperidol and fluphenazine in office patients
2. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses
3. Caution, not cost behind drug debate
4. The effects of phenothiazines on endocrine function: I. Patients with inappropriate lactation and amenorrhoea
5. Tardive dyskinesia and neuroleptic-induced parkinsonism in Japan
6. Antipsychotic drugs: Is more worse? A meta-analysis of the published randomized control trials
7. Incidence and risk factors for severe tardive dyskinesia in older patients
8. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia
9. Early detection of antipsychotic side-effects
10. A comparison of patients' and prescribers' beliefs about neuroleptic side-effects: Prevalence, distress and causation
11. Schizophrenia patients face denial of new drug treatments
12. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine
13. Hyperprolactinaemia in antipsychotic-treated patients: Guidelines for avoidance and management
14. 2 occupancy in low-dose haloperidol treatment
15. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients
16. Treatment of schizophrenia
17. Psychopharmacologic treatment of schizophrenia
18. 2 receptor occupancy with low-dose haloperidol treatment: A PET study
19. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes
20. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment
21. Fluphenazine plasma levels, dosage, efficacy, and side effects
22. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: A rationale and hypothesis
23. The Nithsdale Schizophrenia Surveys. IX: Akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels
24. Optimal dose of neuroleptic in acute schizophrenia: A controlled study of the neuroleptic threshold and higher haloperidol dose
25. The effect of neuroleptics on serum prolactin in schizophrenic patients
26. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications
27. Extrapyramidal syndromes in neuroleptic-treated patients: Prevalence, risk factors, and association with tardive dyskinesia
28. Prophylactic effects of neuroleptics in symptom-free schizophrenics: Roles of dopaminergic and noradrenergic blockers
29. The relationship between plasma haloperidol concentrations and clinical results
30. The coexistence of parkinsonism-like symptoms and tardive dyskinesia
31. Dosage of haloperidol for schizophrenia
32. 2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine
33. Further evidence of a dose - Response threshold for haloperidol in psychosis
34. Tardive dyskinesia in the aged
35. Tardive dyskinesia: Who is at risk?
36. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients
37. Haloperidol plasma levels and clinical response: A therapeutic window relationship
38. Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder
39. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia